Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-08-10), the Forward Annual Dividend Yield of Diamyd Medical AB is 0.00%.
As of today (2026-08-10), the Trailing Annual Dividend Yield of Diamyd Medical AB is 0.00%.
OSTO:DMYD B's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.28 * Ranked among companies with meaningful Forward Dividend Yield % only.
Diamyd Medical AB (OSTO:DMYD B) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Diamyd Medical AB Forward Dividend Yield % Related Terms
OSTO:DMYD B vs VRTX, REGN, RVMD: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Diamyd Medical AB (OSTO:DMYD B) has a Forward Dividend Yield % of 0.00% as of Aug. 10, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Diamyd Medical AB and its competitors. According to the industry distribution chart, Diamyd Medical AB ranks #999999 out of 149 companies in the Biotechnology industry.
Is Diamyd Medical AB's Forward Dividend Yield % too high?
Diamyd Medical AB's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Diamyd Medical AB ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Diamyd Medical AB in the lower half of its industry. The industry median Forward Dividend Yield % is 1.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.28, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (OSTO:DMYD B) is currently considered Possible Value Trap. The stock's GF Value™ is kr13.67, compared to a current price of kr1.01 — trading 92.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Diamyd Medical AB (OSTO:DMYD B), the current Forward Dividend Yield % is 0.00% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (OSTO:DMYD B) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of kr1.01 is trading 92.6% below its estimated GF Value™ of kr13.67.
GuruFocus considers Diamyd Medical AB to be Possible Value Trap.
Key valuation signals for OSTO:DMYD B:
Forward Dividend Yield %: 0.00%
GF Value™: kr13.67 vs. price of kr1.01 (92.6% below fair value)
No single metric tells the full story. See the OSTO:DMYD B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for OSTO:DMYD B
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DMYD B has been successfully added to your 
